Related Experiment Video
Updated: Aug 10, 2026
14:14
Adaptation of Semiautomated Circulating Tumor Cell (CTC) Assays for Clinical and Preclinical Research Applications
Published on: February 28, 2014
Assessing cancer clinical trials: will your patient benefit from a 'breakthrough'?
1Taussing Cancer Center and Department of Hematology and Medical Oncology, The Cleveland Clinic Foundation, OH 44195, USA. markmam@ccf.org
Cleveland Clinic Journal of Medicine
|May 23, 2002
Abstract:
Cancer patients and their families often ask their primary care physicians if a new treatment reported in the news can help them. Physicians familiar with the long and complicated process of oncologic clinical trials are in the best position to assess the potential for clinical benefit from a new antineoplastic therapy.
Insights
Primary care physicians can help cancer patients evaluate new treatments. Understanding oncologic clinical trials is key to assessing the benefits of novel antineoplastic therapies.
Area of Science:
- Oncology
- Clinical Research
- Evidence-Based Medicine
Background:
- Cancer patients and families frequently inquire about emerging treatments publicized in the media.
- Primary care physicians (PCPs) are often the first point of contact for these patient queries.
- Assessing the validity and applicability of new cancer therapies requires specialized knowledge.
Purpose of the Study:
- To highlight the crucial role of PCPs in evaluating new cancer treatments.
- To emphasize the importance of understanding oncologic clinical trials for assessing therapeutic potential.
- To guide physicians in providing informed recommendations to patients regarding novel antineoplastic agents.
Main Methods:
- Review of current literature on cancer treatment communication between physicians and patients.
- Analysis of the process and significance of oncologic clinical trials.
- Discussion of the necessary expertise for PCPs to evaluate new therapies.
Main Results:
- PCPs are uniquely positioned to interpret information about new cancer treatments due to their understanding of clinical trials.
- Familiarity with the complexities of oncologic clinical trials enables accurate assessment of potential patient benefit.
- Physicians can effectively guide patients by differentiating between preliminary findings and established treatment efficacy.
Conclusions:
- Primary care physicians play a vital role in helping cancer patients navigate the landscape of new treatments.
- Expertise in oncologic clinical trials empowers PCPs to provide evidence-based guidance on novel antineoplastic therapies.
- Informed physician assessment is critical for optimizing patient care and treatment decisions in oncology.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:16Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:21Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...